1Tallman M, Nabhan C, Feusner J, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood ,2002,99:759-767.
2Hatake K, Uwai M, Ohtsuki T, et al. Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol, 1997,66 : 13-19.
3Duchesne JC, Mittelbronn MA, Nesbitt LT, et al. Image of the month. Arch Surg,2002, 137: 113-114.
4Astudillo L, Loche F, Reynish W, et al. Sweet's syndrome associated with retinoic acid syndrome in a patient with promyelocytic leukemia. Ann Hematol, 2002, 81 : 111-114.
5Al-Saad K, Khanani MF, Naqvi A, et al. Sweet syndrome developing during treatment with all-trans retinoic acid in a child with acute myelogenous leukemia. J Pediatr Hematol Oncol,2004,26:197-199.
7Cohen PR, Kurzrock R. Sweet's syndrome revisited : a review of disease concepts. Int J Dermatol,2003 ,42 :761-778.
8Haliasos E, Soder B, Rubenstein DS, et al. Pediatric Sweet syndrome and immunodeficiency successfully treated with intravenous immunoglobulin. Pediatr Dermatol ,2005 ,22 :530-535.
9Schneider DT, Schuppe HC, Schwaneider D, et al. Acute febrile dermatosis(Sweet syndrome) as initial presentation in a child with acute myelogenous leukemia. Med Pediatr Oncol,1998,31:178-181.
10Giasuddin ASM, El-Orfi AHA, Ziu MM,et al. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol, 1998,39:940-943.
